Beijing Neurosurgical Institute
This study was designed to identify high platelet reactivity (HPR) who might have in-stent thrombosis in unruptured aneurysm with intracranial stent placement with light transmittance platelet aggregometry (LTA). For HPR patients, higher ischemic stroke rate maybe occurred, and we hypothesis that dose adjustment of aspirin and clopidogrel based on LTA monitoring maybe reduces the rate of ischemic stroke compared to a standard strategy after intracranial stent implantation at early periprocedural period and 1 month follow-up period.
Unruptured Intracranial Aneurysm
Stents
Antiplatelet Drugs
Aspirin and clopidogrel/Ticagrelor
Light transmittance aggregometry
Aspirin and clopidogrel/Ticagrelor
PHASE4
For the patients of unruptured intracranial aneurysms with stent placement, standard antiplatelet therapy (100mg aspirin + 75mg clopidogrel) is considered to be the most effective antiplatelet regimen in reducing ischemic complications. However, despite the use of standard antiplatelet therapy, a number of patients continue to have ischemic events. A hypothesis is that high platelet reactivity (HPR) patients identified by platelet function test have higher ratio of the ischemic events, and dose adjustment of HPR patients reduces the rate of the ischemic complications at early periprocedural period and follow-up period. Objectives: The study aim to evaluated the superiority of the strategy of platelet function test(Monitoring Arm) with the modified strategy in HPR patients compared to the standard strategy (Conventional Arm) whether reduce the primary endpoint after intracranial stent implantation at early periprocedural period (7 days) and 1 months follow-up period.
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 314 participants |
Masking : | NONE |
Primary Purpose : | TREATMENT |
Official Title : | A Study of Platelet Function Test in the Application of Prevention of Ischemic Events After Stent Placement in Intracranial Aneurysms |
Actual Study Start Date : | 2019-07-01 |
Estimated Primary Completion Date : | 2020-07-20 |
Estimated Study Completion Date : | 2020-08-13 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years to 80 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Beijing Neurosurgical Institute and Beijing Tiantan Hospital
Beijing, Beijing City, China, 100050